MedTrace Logo

A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid Leukemia

NCT00601991 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-04-02

No results posted yet for this study

Summary

RATIONALE: Aflibercept may stop the growth of cancer cells by blocking blood flow to the cancer.

PURPOSE: This phase II trial is studying how well aflibercept works in treating patients with advanced refractory, relapsed, or untreated acute myeloid leukemia.

Conditions

Interventions

BIOLOGICAL

VEGF Trap

Drug under investigation

PROCEDURE

Bone marrow biopsy

To determine response to treatment

PROCEDURE

bone marrow aspiration

To determine response to treatment

PROCEDURE

Venipuncture

For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Stephen Strickland, MD · Vanderbilt-Ingram Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-03-31
Completion
2009-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00601991 on ClinicalTrials.gov